Screener
Iovance Biotherapeutics, Inc. IOVA Business Segments — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Cost of sales ** | $43,595 | $48,881 | $86,093 | $91,595 |
| Research and development ** | 58,851 | 77,928 | 121,338 | 153,895 |
| Selling, general, and administrative ** | 39,272 | 37,567 | 78,221 | 81,366 |
| Depreciation and amortization | 9,500 | 9,350 | 18,039 | 17,415 |
| Total costs and expenses | $151,218 | $173,726 | $303,691 | $344,271 |
| Loss from operations | (51,905) | (113,774) | (132,948) | (234,995) |
| Other income | ||||
| Interest and other income, net | 3,217 | 4,104 | 4,550 | 7,324 |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s business segments — D&A?
- Iovance Biotherapeutics, Inc. (IOVA) reported business segments — D&A of $9.5M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s business segments — D&A changed year-over-year?
- Iovance Biotherapeutics, Inc.'s business segments — D&A increased by 1.6% year-over-year, from $9.35M to $9.5M.
- What does business segments — D&A mean?
- This reflects the systematic allocation of the cost of tangible and intangible assets over their useful lives. It provides insight into the capital intensity of the business and the ongoing investment required to maintain operational infrastructure.
Ask your AI about Iovance Biotherapeutics, Inc.'s business segments — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude